메뉴 건너뛰기
Headache
Volumn 47, Issue 8, 2007, Pages 1200-1203
Efficacy of duloxetine as a migraine preventive medication: Possible predictors of response in a retrospective chart review
Author keywords

Anxiety; Duloxetine; Migraine; Preventative
Indexed keywords

DULOXETINE;
EID: 34648812736     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2007.00886.x     Document Type: Review
Times cited : (28)
References (8)
  • 1
    • 0034177434 scopus 로고    scopus 로고
    • Selective serotonin reuptake inhibitors versus tricyclic antidepressants
    • Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants. J Affect Disord. 2000 58:19 36.
    • (2000) J Affect Disord. , vol.58 , pp. 19-36
    • Anderson, I.M.1
  • 2
    • 0026683146 scopus 로고
    • Fluoxetine prophylaxis of migraine
    • Adly C, Strasmanis J, Chesson A. Fluoxetine prophylaxis of migraine. Headache. 1992 32:101 104.
    • (1992) Headache. , vol.32 , pp. 101-104
    • Adly, C.1    Strasmanis, J.2    Chesson, A.3
  • 3
    • 0027944865 scopus 로고
    • Double-blind trial of fluoxetine: Chronic daily headache and migraine
    • Saper J, Silberstein SD, Lake AS, et al. Double-blind trial of fluoxetine: Chronic daily headache and migraine. Headache. 1994 34:297 502.
    • (1994) Headache , vol.34 , pp. 297-502
    • Saper, J.1    Silberstein, S.D.2    Lake, A.S.3
  • 4
    • 0033930090 scopus 로고    scopus 로고
    • Venlafaxine extended-release for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical practice
    • Adelman L, Adelman JU, Von Seggern R, et al. Venlafaxine extended-release for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical practice. Headache. 2000 40:572 580.
    • (2000) Headache. , vol.40 , pp. 572-580
    • Adelman, L.1    Adelman, J.U.2    Von Seggern, R.3
  • 5
    • 34648825958 scopus 로고    scopus 로고
    • Duloxetine for the treatment of major depressive disorder: Safety and tolerability associated with dose escalation
    • Wohlreich MM, Mallinckrodt C, Parakash A, et al. Duloxetine for the treatment of major depressive disorder: Safety and tolerability associated with dose escalation. Depress Anxiety. 2006 0:1 12.
    • (2006) Depress Anxiety. , vol.0 , pp. 1-12
    • Wohlreich, M.M.1    Mallinckrodt, C.2    Parakash, A.3
  • 6
    • 0036112313 scopus 로고    scopus 로고
    • Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial
    • Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. J Clin Psychiatry. 2002 63:225 231.
    • (2002) J Clin Psychiatry. , vol.63 , pp. 225-231
    • Goldstein, D.J.1    Mallinckrodt, C.2    Lu, Y.3
  • 7
    • 0141731324 scopus 로고    scopus 로고
    • Duloxetine in treatment of anxiety symptoms associated with depression
    • Dunner DL, Goldstein DJ, Mallinckrodt C, et al. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety. 2003 18:53 61.
    • (2003) Depress Anxiety. , vol.18 , pp. 53-61
    • Dunner, D.L.1    Goldstein, D.J.2    Mallinckrodt, C.3
  • 8
    • 14844352158 scopus 로고    scopus 로고
    • The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed patients
    • Farabaugh A, Mischalon D, Fava M, et al. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed patients. Int Clin Psychopharmacol. 2005 20:87 91.
    • (2005) Int Clin Psychopharmacol. , vol.20 , pp. 87-91
    • Farabaugh, A.1    Mischalon, D.2    Fava, M.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.